Der Ophthalmologe

, Volume 101, Issue 7, pp 741–765 | Cite as

Tropenophthalmologie—Prävention und Therapie

„Vision 2020—das Recht auf Sehen“
  • V. Klauß
  • U. C. Schaller


Weltweit sind 45 Mio. Menschen blind, 180 Mio. leiden an Sehbehinderung; 90% aller blinden Menschen leben in der „Dritten Welt“; 80% der Blindheit auf dieser Erde wären vermeidbar. Der volkswirtschaftliche Schaden durch Blindheit betrug weltweit rund 19 Milliarden US$ für das Jahr 2000. Die wichtigsten Herausforderungen der WHO-Kampagne „Vision 2020—the right to sight“ sind, die Zahl der Kataraktoperationen zu erhöhen und Augenerkrankungen wie Trachom, Onchozerkose sowie die Ursachen der Kinderblindheit zu bekämpfen. Bis zum Jahr 2020 sollen insgesamt 100 Mio. Menschen vor der Erblindung bewahrt werden.


Tropenophthalmologie Vision 2020 Epidemiologie Prävention 

Tropical ophthalmology—prevention and therapy

“Vision 2020—the right to sight”


Worldwide 45 million people are blind, 180 million people are visually handicapped, 90% of all blind people are living in developing countries and 80% of blindness is preventable. The global economic productivity loss due to blindness was estimated to be 19 billion US$ in the year 2000. The initiative “Vision 2020—the right to sight” aims to increase the cataract surgical rate and to eliminate diseases such as trachoma and onchocerciasis as well as avoidable blindness in children. It is planned that blindness in 100 million people can be avoided by the year 2020.


Tropical ophthalmology Vision 2020 Epidemiology Prevention 



Keine Angaben


  1. 1.
    Bailey R, Lietman T (2001) The safe strategy for the elemination of trachoma by 2020: Will it work? Bull WHO 79:233–236PubMedGoogle Scholar
  2. 2.
    Belfort R, Muccioli C (1995) Experience of HIV/AIDS and the eye in Brazil, South Amerika. Community Eye Health 8:26–27Google Scholar
  3. 3.
    Belfort R (2000) The Ophthalmologist and the global impact of the AIDS epidemic LV Edvard Jackson memorial lecture. Am J Ophthalmol 129:1–8CrossRefPubMedGoogle Scholar
  4. 4.
    Calcutt C, Murray ADN (1998) Untreated essential infantile esotropia: factors affecting the developement of amblyopia. Eye 12:167–172PubMedGoogle Scholar
  5. 5.
    Courtright P, Lewallen S (1998) Ocular manifestations of leprosy. In: Johnson GJ, Minassian DC, Weale R (eds) The epidemiology of eye disease. Chapman and Hall Medical, LondonGoogle Scholar
  6. 6.
    Courtright P, Lewallen S, Tungpakorn N et al. (2001) Cataract in Leprosy patients: cataract surgical coverage, barriers to acceptance of surgery, and outcome of surgery in a population based survey in Korea. Br J Ophthalmol 85:643–647CrossRefPubMedGoogle Scholar
  7. 7.
    Dandona L, Williams JD, Williams BC, Rao GN (1998) Population-based assessment of childhood blindness in Southern India. Arch Ophthalmol 116:545–546Google Scholar
  8. 8.
    Dawson C, Schachter J (1999) Can blinding trachoma be eliminated worldwide? Arch Ophthalmol 117:974PubMedGoogle Scholar
  9. 9.
    Foster A (2001) Cataract and „Vision 2020—the right to sight“ initiative. Br J Ophthalmol 85:635–639CrossRefPubMedGoogle Scholar
  10. 10.
    Fransen L, Klauß V (1988) Neonatal ophthalmia in the developing world. Int Ophthalmol 11:189PubMedGoogle Scholar
  11. 11.
    Frick KD, Lietman TM, Holm SO et al. (2001) Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bulletin of the WHO 79:201–207Google Scholar
  12. 12.
    Frick KD, Foster A (2003) The magnitude and cost of global blindness: an increasing problem that can be alleviated. Am J Ophthalmol 135:471–476CrossRefPubMedGoogle Scholar
  13. 13.
    Grehn F (2001) World health problem of glaucoma. J Glaucoma 10:S2–S3CrossRefPubMedGoogle Scholar
  14. 14.
    Hero M, Harding SP, Riva CE et al. (1997) Photographic and angiographic characterization of the retina of Keniyan children with severe malaria. Arch Ophthalmol 115:997–1003PubMedGoogle Scholar
  15. 15.
    Huismans H (1979) Tierische Parasiten des menschlichen Auges. Enke, StuttgartGoogle Scholar
  16. 16.
    Johnson GJ (2000) Improving outcome of cataract surgery in developing countries. Lancet 355:158–159CrossRefPubMedGoogle Scholar
  17. 17.
    Jyotirmay B, Madhavan HN, George AE et al. (2000) Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol 129:9–15CrossRefPubMedGoogle Scholar
  18. 18.
    Kapoor H, Chatterjee A, Daniel R, Foster A (1999) Evaluation of visual outcome of cataract surgery in an Indian eye camp. Br J Ophthalmol 83:343–346PubMedGoogle Scholar
  19. 19.
    Kennedy D (2002) Good news on a tropical disease. Science 296:1365CrossRefPubMedGoogle Scholar
  20. 20.
    Kestelyn P, van de Perre P, Rouvroy D et al. (1985) A prospective study of the ophthalmologic findings in the aquired immune deficiency syndrome in Africa. Am J Ophthalmol 100:230–238PubMedGoogle Scholar
  21. 21.
    Kestelyn P (1999) The epidemiology of CMV retinitis in Africa. Ocular Immunol Inflamm 7:173–177CrossRefGoogle Scholar
  22. 22.
    Klauß V (1986) Conjunctivitis durch Chlamydien und Parasiten. Fortschr Ophthalmol 83:72PubMedGoogle Scholar
  23. 23.
    Klauss V (2000) Tropische Ophthalmologie. In: Lang W, Löscher T (Hrsg) Tropenmedizin in Klinik und Praxis. Georg Thieme, StuttgartGoogle Scholar
  24. 24.
    Lewallen S (1994) Herpes Zoster Ophthalmicus in Malawi. Ophthalmology 101:1801–1804PubMedGoogle Scholar
  25. 25.
    Lewallen S, Kumwenda J, Maher D, Harries AD (1994) Retinal findings in Malawian patients with AIDS. Br J Ophthalmol 78:757–759PubMedGoogle Scholar
  26. 26.
    Lewallen S, Courtright P (1997) HIV and Aids and the Eye in developing countries. Arch Ophthalmol 115:1291–1295PubMedGoogle Scholar
  27. 27.
    Schaller UC, Klauss V (2001) Is Credé’s prophylaxis still valid? Bulletin of the WHO 79:262–263Google Scholar
  28. 28.
    Schaller UC, Walli RK, Mueller AJ, Klauß V (1999) Regression der Zytomegalievirus-Retinitis bei AIDS-Patienten ohne systemische Anti-Zytomegalievirus-Erhaltungstherapie unter hochaktiver antiretroviraler Therapie (HAART). Ophthalmologe 96:829–831CrossRefPubMedGoogle Scholar
  29. 29.
    Sommer A (1982) Nutritional blindness—xerophthalmia and keratomalacia. Oxford University Press, LondonGoogle Scholar
  30. 30.
    Sovani I, Humphrey JH, Kuntinalibronto DR et al. (1994) Response of biot’s spot to a single oral 100.000- or 200.000-IU dose of vitamin A. Am J Ophthalmol 118:792–796PubMedGoogle Scholar
  31. 31.
    Spaide RF, Gaissinger A, Podhorzer JR (1995) Risk factors for cotton-wool spots and for Cytomegalovirus retinitis in patients with human immunodeficiency virus infection. Ophthalmology 102:1860–1864PubMedGoogle Scholar
  32. 32.
    Srinivasa DK, D’Souza V (1987) Economic aspects of an epidemic of Haemorrhagic conjunctivitis in a rural community. J Epidemiol Com Health 41:79–81Google Scholar
  33. 33.
    Tarantola DJ, Mann JM (1996) Global expansion of HIV infection and AIDS. Hosp Pract (Off Ed) 31:63–79Google Scholar
  34. 34.
    Umeh RE, Umeh OC (1997) Causes and visual outcome of childhood eye injuries in Nigeria. Eye 11:489–495PubMedGoogle Scholar
  35. 35.
    Waddel KM, Lewallen S, Lucas SB et al. (1996) Carcinoma of the conjunctiva and HIV infection in Unganda and Malawi. Br J Ophthalmol 80:503–508PubMedGoogle Scholar
  36. 36.
    West S, Sommer A (2001) Prevention of blindness and priorities for the future. Bull WHO 79:244–248PubMedGoogle Scholar
  37. 37.
    Zumla A, Sawa D, Wheeler RB et al. (1991) Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 85:227–229CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Augenklinik der Ludwig Maximilians UniversitätMünchen
  2. 2.Department of Ophthalmology, Kenyatta National HospitalUniversity of NairobiNairobiKenia
  3. 3.Augenklinik der Ludwig Maximilians UniversitätMünchen

Personalised recommendations